



- Industry association representing the off-patent sector
- > Represents 85% of the sector
- Some of the biggest pharmaceutical companies you have never heard of
- >40 smaller companies

SANDOZ



AVITASS

teva



Off-patent sector

MedicinesUK[®]

- > A new medicine developer gets exclusive rights for approx. 20 years
- > 10 years of development, testing, approvals
- > 10 years of exclusive sales
- > Then other companies can copy the drug and sell it



Product range

- Long-established oral solid doses
- > Paracetamol, antibiotics





- Newer, complex hospitaladministered infusions (biosimilars) to treat:
 - Cancer
 - Auto-immune conditions
 - etc



> Key characteristics of generics

> High volumes

80% of all medicines used in NHS

2 billon prescription packs a year

More over-the-counter



> Key characteristics of generics

>Low cost

80% less than original on average

800m packs a month at 80p

Paracetamol 1 per pill





Prices stable or falling

Antibiotics prices fell 10% in past 4 years

Amoxicillin prices fell 20%

Inflation rate 23%,

producer costs up 32%







Perspective

>UK medicines carbon footprint (inc. on patent medicines):

4-10 Mt CO2e pa

0.01 to 0.02% of global emissions


Equivalent to Jamaica's emissions
















> What are we doing to decarbonize?








> What are we doing to decarbonize?

SANDOZ 90%

of European electricity from solar site in Spain







> What are we doing to decarbonize?

AVITASS

100%

of European electricity in manufacturing sites is renewable







What are we doing to decarbonize?



100%

of electricity in manufacturing sites in Ireland and Germany is renewable







What are we doing to decarbonize?


accord We make it better

100%

of electricity in UK manufacturing sites is renewable



The challenges of a complex global supply chain



Scope 3 Emissions Reporting

